/IRD
IRD Stock - Opus Genetics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.00+1.01%
+$0.02 (+1.01%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.76
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+250.0%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IRD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.98 – $2.02
TARGET (TP)$7.00
STOP LOSS$1.84
RISK/REWARD1:31.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$2.59
52W Low$0.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.99M | $19.05M | $39.85M | $589,000 | N/A |
| Gross Profit | $10.99M | $19.05M | $39.85M | $589,000 | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-62,074,000 | $-10,563,000 | $18.23M | $-22,705,000 | $-19,968,000 |
| Net Income | $-57,532,000 | $-9,986,000 | $17.89M | $-56,693,000 | $-24,620,000 |
| Net Margin | -523.4% | -52.4% | 44.9% | -9625.3% | N/A |
| EPS | $-2.15 | $-0.46 | $0.90 | $-3.82 | $-5.28 |
Company Overview
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 291.7% Upside
Now
$6
Low
$8
Average
$9
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | B. Riley Securities | Initiation | Buy | $9 |
| November 25th 2025 | Piper Sandler | Initiation | Overweight | $7 |
| October 29th 2025 | Wedbush | Initiation | Outperform | $8 |
| October 16th 2025 | Chardan Capital Markets | Initiation | Buy | $9 |
| April 11th 2025 | Craig Hallum | Initiation | Buy | $6 |
| November 13th 2024 | H.C. Wainwright | Resumed | Buy | $8 |
Earnings History & Surprises
IRDBeat Rate
50%
Last 12 quarters
Avg Surprise
-37.1%
EPS vs Estimate
Beats / Misses
6/6
Last 12 quarters
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
-315.2%
$-0.22vs$-0.05
Q2 24
-61.1%
$-0.29vs$-0.18
Q3 24
-20.0%
$-0.30vs$-0.25
Q4 24
+3.3%
$-0.29vs$-0.30
Q1 25
-273.5%
$-1.27vs$-0.34
Q2 25
+5.9%
$-0.32vs$-0.34
Q3 25
+52.0%
$-0.12vs$-0.25
Q4 25
+14.3%
$-0.12vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.25 | $-0.12 | +52.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.34 | $-0.32 | +5.9% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.34 | $-1.27 | -273.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.30 | $-0.29 | +3.3% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-0.18 | $-0.29 | -61.1% | ✗ MISS |
Q1 2024 | Mar 9, 2024 | $-0.05 | $-0.22 | -315.2% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.22 | $0.25 | +211.8% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.23 | $-0.24 | -4.7% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.15 | $-0.28 | -79.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $1.58 | — | — |
Q3 2022 | Sep 30, 2022 | $-0.28 | $-0.22 | +21.6% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-0.25 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.35 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.35 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.25 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.52 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-3.57 | — | — |
Latest News
B. Riley Securities Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Dec 10, 2025, 12:33 PM
Opus Genetics rises as eye disease study to proceed without changes
📈 PositiveSeeking Alpha•Dec 9, 2025, 05:59 PM
Opus Genetics Says IDMC Issues Positive Recommendation To Continue As Planned In Phase 1/2 BEST1 Clinical Trial, Evaluating Opgx-BEST1 In Participants With Best Disease
📈 PositiveBenzinga•Dec 9, 2025, 12:06 PM
Piper Sandler Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $7
📈 PositiveBenzinga•Nov 25, 2025, 02:27 PM
Chardan Capital Maintains Buy on Opus Genetics, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 01:42 PM
Opus Genetics Doses First Participant In OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial For Best Disease, Initial Data Expected Q1 2026
📈 PositiveBenzinga•Nov 13, 2025, 12:07 PM
Opus Genetics Q3 EPS $(0.25) Misses $(0.13) Estimate, Sales $3.079M Beat $3.075M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 12:10 PM
Chardan Capital Maintains Buy on Opus Genetics, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 7, 2025, 02:55 PM
Opus Genetics shares are trading lower after the company announced a $23 million registered direct offering.
📉 NegativeBenzinga•Nov 6, 2025, 04:04 PM
Opus Genetics Announces Registered Direct Offering For Gross Proceeds ~$23M
➖ NeutralBenzinga•Nov 6, 2025, 12:09 PM
Opus Genetics Announce Completes Type B Regenerative Medicine Advanced Therapy Meeting With FDA Regarding OPGx-LCA5
➖ NeutralBenzinga•Nov 6, 2025, 12:09 PM
Wedbush Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $8
📈 PositiveBenzinga•Oct 29, 2025, 12:26 PM
Chardan Capital Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Oct 16, 2025, 12:37 PM
Opus Genetics Reports Results Showing Vision Gains In Teenagers With Rare Eye Disease
📈 PositiveBenzinga•Sep 30, 2025, 11:04 AM
Opus Genetics Announces First Patient Has Been Dosed In Its Phase 3 Lynx-3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Treating Chronic Night Driving Impairment In Keratorefractive Patients With Reduced Mesopic Vision
📈 PositiveBenzinga•Sep 4, 2025, 12:14 PM
Opus Genetics Appoints Veteran Biotech Executive Rob Gagnon As Chief Financial Officer
📈 PositiveBenzinga•Sep 2, 2025, 12:14 PM
Opus Genetics Enters Agreements For Private Placement Of Shares; Private Placement Gross Proceeds About $3.5M; Proceeds To Expedite Manufacturing For Gene Therapy Candidates
📈 PositiveBenzinga•Aug 25, 2025, 09:24 PM
Opus Genetics Announces FDA Clearance Of Its IND Application ForIts Gene Therapy Candidate, OPGx-BEST1
📈 PositiveBenzinga•Aug 18, 2025, 12:01 PM
Frequently Asked Questions about IRD
What is IRD's current stock price?
Opus Genetics, Inc. (IRD) is currently trading at $2.00 per share. The stock has moved +1.01% today.
What is the analyst price target for IRD?
The average analyst price target for IRD is $7.00, based on 1 analyst.
What sector is Opus Genetics, Inc. in?
Opus Genetics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IRD's market cap?
Opus Genetics, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does IRD pay dividends?
No, Opus Genetics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to IRD for comparison